Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mirror Image who wrote (1481)	9/1/2015 2:01:39 PM
From: eico20	Read Replies (2) of 2026

great posts and numbers MI, I agree a surprise Femprox partner would be huge and it helps keep the expected dilution down. Fis. positive news is a real mover as well, as you said a positive read on the Rayva 2A is expected. The company has been beaten up for so long they need significant cash and revenue to really get the share price moving. It does all seem to be coming into place after a very long time. I expect the Fis. trial to be positive given the competitive SERM androxal from repros had very robust data, and APRI has designed the trial very much in line with what the FDA has asked for in terms of endpoints that show clinical benefits beyond raising T and preserving fertility.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next